Next Phase Newsletter

A venture capital investment firm based in Western Europe. The firm is actively seeking medtech investment opportunities from Seed to Series B financing rounds, though the firm’s sweet spot is leading Series A investments. Initial check sizes can largely vary; the firm can invest anywhere from €1-5M, and seeks to invest €5-8M over the life of investment. With the current fund, the firm manages 5 portfolio companies, and seeks to invest in ~12 companies, for which the firm estimates 2/3 will be Europe/Israel-based companies, and 1/3 will be USA-based companies. Currently, the firm is not evaluating opportunities outside of USA, Europe, and Israel.

The firm is focused on investing in innovative medical devices that address cardiovascular or neurovascular disease. The firm does not invest in other sectors such as therapeutics, diagnostics, or digital health. Within medical devices, the firm is open to both pre-clinical (prototype) and clinical technologies. The firm has primarily evaluated PMA devices but is open to 510k regulatory pathways. The firm may consider other types of devices on a highly selective basis, but even such opportunities must have some connection or relevance to cardiovascular disease.

The firm prefers to lead investment rounds and seek board representation, though the firm can also co-invest alongside syndicates. Through the firm’s relationship with a large strategic platform, the firm is uniquely positioned to create value for their portfolio companies in the European market. Through this sister company relationship, the firm has access to a wide network including large hospitals, clinical sites, physicians, KOLs, etc. and can provide strategic advice on market strategy.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Funded in October 2017, the family office focused on early-stage Biotech/Medtech investments primarily in Switzerland. The firm has accumulated over 40M CHF investment amount over the past 24 months. The firm’s biggest investment in a single company is CHF 5M thus far, but the size of investment could vary. The firm looks for companies located around the globe, with a preference in Switzerland or Europe. The firm is actively seeking new investment opportunities.

The firm looks to invest 70% in Therapeutics, 20% in Medical Devices, and 10% Digital Health/Others. In Therapeutic areas, the firm might invest half in early-stage and another half in later-stage. The firm is opportunistic in indications and willing to consider orphan indications. The firm seeks technologies that could fill unmet medical needs.

The firm has no specific requirements on companies. The firm currently acts as lead investors for two companies, and has represented in five boards. The firm might take a board seat depends on applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

An Innovation Lab that is the open innovation arm of a Japan-headquartered global leader in robotics and automation for manufacturing of electronic devices and the automotive industry. The firm has offices in Cupertino, CA and New York. The firm seeks to identify investment and partnership opportunities that align with its parent company’s business, and is currently focused on early stage (Seed to Series A) companies. The firm has a global outlook and is seeking opportunities in North America, Europe, Asia and beyond.

Within life sciences and healthcare sectors, the firm is interested in the following verticals: support robots, human behavior monitors, and vital sensors. The firm is particularly interested in technologies that address the aging population and those that can significantly improve the quality of life and promote more efficient care management and independence. The firm will openly consider IoT devices and platforms that address this market. The firm is not interested in traditional therapeutics and diagnostics companies.

The firm can act as either lead or co-investor in the companies they invest in. Beyond investment, the firm seeks to collaborate in various ways such as assisting with generating PoC data, assisting further clinical development, navigating and entering the Japanese market, etc. The firm closely communicates with its parent corporation headquarters to support these initiatives.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

Founded in 2019, the Venture Capital firm a space technology and human longevity-focused VC based in New York, USA. The firm had its hard launch in December 2020 at TechCrunch Sessions. The firm invests in Pre-seed, Seed, Seed+ companies at $200K with a possible follow-on of $400K and Series A & B rounds at $800K with a potential $1.6M follow-on. The firm will consider opportunities primarily in the Americas, UK, and EU. Also, the firm actively supports companies by providing connections to human capital providers, governmental entities, and suitable investors to help founders grow their business.

The firm will look at a broad spectrum of products and services within space technology and human longevity. The partners had previously invested in 20+ early-stage technology companies/ funds with active private deal-flow in the verticals of space, healthcare, and robotics. The firm is investing in biomarkers, diagnostics, digital health, and therapeutics (RX and OTC), dealing with the hallmarks of aging on the longevity side of things.

The firm will invest in privately held companies only and will participate as a co-investor. The firm prefers to invest in companies with at least three founders and will not invest in sole founder companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email LHI@lifesciencenation.com.

A venture capital firm is founded in 2010 with headquarters in Silicon Valley. Over the past 9 years, the firm has invested over 160 startups in deep tech-focused areas such as SaaS, Biotech, AI chips, Fintech, Blockchain, and Semiconductors; with 4 unicorns in the firm’s portfolio. The firm recently closed its fourth fund, of $50M AUM, and is actively seeking investment opportunities across a wide range of industries. Within the Life Science area, the firm is interested in Therapeutics, Medical Devices, Digital Health, and Diagnostics. The fund will focus on investing in the US or companies who are interested in entering the US market. On average, the typical size of investment is $0.5 – 1M but the firm also has follow-up investment strategies. The firm seeks to invest in early-stage companies, which Seed to Pre-A round is their sweet spot.

The firm is an opportunistic investor and will consider therapeutics, medical devices, diagnostics, and digital healthcare companies. The firm is open to a wide range of technologies including novel techniques. Within Medtech, the firm is strongly interested in robotics, semiconductors, sensors, AI modeling diseases, and telemedicine. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA.

The firm has a preference for companies with a full-time founding team and was founded recently (no more than 10 years). The firm can act as either a lead investor or co-investor depends on applicable cases. If the firm acts as the lead investor, it will seek a board seat or an observer seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A newly established venture capital firm based in the USA has just successfully closed the first round of their fund ($20M target), and made its first investment. The firm invests globally in medically related early-stage companies. Initial size of investment ranges from $250 – 500K. While the firm is focused on USA-based companies, the firm is open to considering companies across the globe.

The firm invests in medical technology and digital health companies. While the founder has decades of experience as an oculofacial plastic surgeon, the firm is generally opportunistic and will consider any promising technologies that address unmet medical needs. The firm has looked at AI companies, digital health/software companies implementable in medical practices, etc. In terms of stage of development, the firm is open to investing as early as pre-prototype, given that the company has properly researched the idea behind their technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.